Frontiers in endocrinology

Tirzepatide and the risk of asthma attacks in people with type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Tirzepatide (TZP) may provide anti-inflammatory benefits for patients with asthma and type 2 diabetes.

  • TZP acts as a receptor agonist for both GIP and GLP-1, which are involved in glucose metabolism and appetite regulation.
  • The effectiveness of TZP in reducing acute asthma exacerbations among patients with asthma and type 2 diabetes is being evaluated.
  • Comparative effectiveness assessments are planned against other antidiabetic agents.
  • This research highlights potential dual benefits of TZP for individuals managing both asthma and type 2 diabetes.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Jun '22
Risk of new atrial fibrillation in type 2 diabetes patients using three common diabetes medicines
top 2% journal
cited by 41 papers
research support, non-u.s. gov't
Sep '25
Link between diabetes drugs (SGLT2 inhibitors and GLP-1 receptor agonists) and Parkinson's disease risk in type 2 diabetes patients
top 10% journal
cited by 4 papers
meta-analysis
Dec '24
Kidney health in type 2 diabetes with moderate heart risk using four common diabetes medicines
top 5% journal
cited by 5 papers
journal article
Sep '25
GLP-1 receptor agonists and their link to dementia risk compared to other diabetes medicines in a large group of type 2 diabetes patients
top 2% journal
cited by 3 papers
multicenter study
Jan '24
SGLT2 Inhibitors and Kidney Stone Risk in People with Type 2 Diabetes
top 2% journal
cited by 44 papers
journal article
Mar '23
Heart-related outcomes with SGLT2 inhibitors compared to DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced or preserved pumping ability
top 2% journal
cited by 32 papers
journal article
Sep '25
Comparing GLP-1 and combined GLP-1/GIP treatments for lowering serious liver problems in type 2 diabetes
top 5% journal
cited by 6 papers
comparative study
Oct '21
Comparing diabetes drugs for people with heart disease: a network analysis of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors
cited by 44 papers
systematic review
May '26
Long-term risk of joint replacement linked to second-choice diabetes medicines in type 2 diabetes
top 10% journal
journal article
Jul '25
Brain cell loss and stroke risk after Semaglutide and Tirzepatide in people with diabetes and obesity
top 2% journal
cited by 23 papers
research support, non-u.s. gov't

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief